TA-TMA Transplant Associated Thrombotic MicroAngiopathy Assays
sC5b9 - CH50 - Eculizumab
Comprehensive. Life-Saving. Time Saving.
What is TMA?
Thrombotic microangiopathies (TMA) are a category of diseases linked by endothelial injury leading to aggregation of platelets on the damaged endothelium, microvascular thrombosis and organ dysfunction related to microvascular injury.
Transplant-associated thrombotic microangiopathy (TA-TMA) occurs when endothelial injury in the context of allogeneic hematopoietic cell transplantation (allo-HCT) causes microangiopathic hemolytic anemia and platelet consumption, resulting in microvascular thrombosis and fibrin deposition in the microcirculation.
Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of stem cell transplants that can occur with peripherally mobilized stem cells or bone marrow-derived stem cells.
Contact us to learn more about the TA-TMA assays
33334 - TA-TMA CH50 33335 - TA-TMA sC5b-9 33336 - TA-TMA Eculizumab
Next Day Results for sC5b-9, CH50 and Eculizumab
Get comprehensive results with the fastest turn around time...anywhere.
Eurofins Viracor's TA-TMA testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9. Our comprehensive approach ensures that clinicians receive detailed results across all three critical areas, empowering them to make informed decisions about patient treatment promptly, thanks to our industry-leading 24 hour turnaround time.
Transplant Associated Thrombotic MicroAngiopathy
How Does TMA Occur?
Transplant-associated thrombotic microangiopathy (TA-TMA) occurs when endothelial injury in the context of allogeneic hematopoietic cell transplantation (allo-HCT) causes microangiopathic hemolytic anemia and platelet consumption, resulting in microvascular thrombosis and fibrin deposition in the microcirculation.
How is it Diagnosed?
CBC & Schistocyte Smear
LDH & Haptoglobin
PT, Aptt & Fibrinogen
DCT
Serum C5b9
Work up for Viral Infections
Urine for Proteinuria
TA-TMA Testing: Faster Results and a Comprehensive Approach
Eurofins Viracor's TA-TMA (Transplant-associated thrombotic microangiopathy) testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9.
- Eculizumab
- CH50
- sC5b-9
Learn more in our Abstract Poster:
Discovering & Developing Next Generation Diagnostic Tools for the Early Detection of TA‑TMA
Thrombotic microangiopathy after transplant (TA‑TMA) remains a serious and often under‑recognized complication in transplant patients. Our latest research explores innovative diagnostic approaches designed to enable earlier identification, improved risk stratification, and more timely clinical intervention. Read our abstract poster to learn how Viracor is advancing next‑generation tools to support better outcomes for patients at risk of TA‑TMA.